Alzheimer’s Biomarker Data Ready For Release; Analyses Pose Next Challenge
Executive Summary
Biomarker data for Alzheimer's disease will be publicized early this year, one of a number of government and private efforts aimed at pushing research forward in 2008
You may also be interested in...
Alzheimer’s Plan Emphasizes Acceleration, Sets Timeline On Prevention, Cure
Ambitious draft plan from the Obama administration includes public/private efforts to shorten drug development times and pick up the pace of clinical trials, including more efficient ways of identifying and enrolling participants.
Alzheimer’s Report To Congress: Faster FDA Approval, Orphan-Like Exclusivity
The development of biomarkers and other steps to speed FDA approval of drugs for Alzheimer's disease was recommended by the Alzheimer's Study Group as part of a 1strategic plan presented to the Senate Select Committee on Aging March 25
Alzheimer’s Report To Congress: Faster FDA Approval, Orphan-Like Exclusivity
The development of biomarkers and other steps to speed FDA approval of drugs for Alzheimer's disease was recommended by the Alzheimer's Study Group as part of a 1strategic plan presented to the Senate Select Committee on Aging March 25